The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Atacicept, Mavrilimumab Drug Updates, Trials, Safety Data

Atacicept, Mavrilimumab Drug Updates, Trials, Safety Data

September 1, 2014 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The primary endpoint (the proportion of patients who achieved a ≥1.2 decrease from baseline in DAS28‑CRP at Week 12) was achieved in 41%, 61%, 54%, 67% and 35% of patients, respectively. At Week 12, 56% of mavrilimumab-treated patients compared with 35% of placebo-treated patients achieved the primary endpoint. All ACR20 categories were reached and all mavrilimumab-treated patients showed a response by Week 2. A dose-dependent decrease in biomarkers was observed at Week 12. Adverse reactions were mild to moderate, with no significant hypersensitivity reactions or infections.

You Might Also Like
  • Rheumatology Drug Updates, Trials, Safety Data
  • Rheumatology Drug Updates, Trials, Safety Data
  • Rheumatology Drug Updates, Trials, Safety Data
Explore This Issue
September 2014
Also By This Author
  • Celecoxib & Cardiovascular Death: NSAID Safety Under Review

In the subsequent Phase 2b study (EARTH EXPLORER-1), mavrilimumab achieved its primary endpoint in 326 patients with moderate-to-severe RA with background MTX following 24 weeks of treatment. Patients received mavrilimumab every two weeks at a low (30 mg), medium (100 mg) or high (150 mg) dose.4 The ACR20 response for active-treated groups compared with placebo was 73% and 25% (p<0.001), respectively. The reduction in the mean DAS28 score at Day 85 was -1.9 and -0.68 (p<0.001), respectively. Secondary endpoints of ACR50, ACR70 and DAS28 remission score achieved statistical significance for the high-mavrilimumab dose. Rapid improvements in patient-reported outcomes, including disability, pain and fatigue, were achieved. The most common adverse events were headache, nasopharyngitis, hypertension, bronchitis and RA worsening.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Drug Safety

In June, the Food and Drug Administration (FDA) publicly released more than 3 million adverse drug event reports and medication errors in a program called Open FDA.5 The FDA hopes that doing this will lead to new medication applications and research. The data released included reports from 2004–13, which prior to this project were only available through the Freedom of Information Act. The Open FDA Project can be accessed via https://open.fda.gov. More information is available on the FDA’s website.


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City, and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2014 Jun 10. doi: 10.1136/annrheumdis-2013-205067. [Epub ahead of print].
  2. AstraZeneca announces MedImmune’s mavrilimumab and sifalimumab both met primary endpoints in Phase IIb studies. May 12, 2014. http://www.astrazeneca.com/Media/Press-releases/Article/20140512–astrazeneca-announces-medimmunes-mavrilimumab-sifalimumab-met-primary-endpoints-Phase-IIb-studies.
  3. Burmester GR, Weinblatt ME, McInnes IB, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1445–1452.
  4. Burmester GR, Takeuchi T, Barbarash O, et al. Presentation #1733: Early and sustained improvement in pain and physical function as measured by visual analog scale and short form-36 physical component summary score in rheumatoid arthritis patients treated with mavrilimumab, an investigational anti-GM-CSFR-alpha monoclonal antibody, in a phase 2a study. ACR/ARHP 2013, San Diego, Oct. 25–30, 2013. https://acr.confex.com/acr/2013/recordingredirect.cgi/id/2398.
  5. Al-Faruque F. Open FDA project releases millions of reports. The Hill. June 2, 2014. http://thehill.com/policy/healthcare/207922-open-fda

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Rheumatoid Arthritis, Safety, SLE (Lupus) Tagged With: atacicept, Biologics, drug, Kaufman, mavrilimumab, Research, Rheumatoid arthritis, rheumatologist, rheumatology, rituximab, Safety, Systemic lupus erythematosusIssue: September 2014

You Might Also Like:
  • Rheumatology Drug Updates, Trials, Safety Data
  • Rheumatology Drug Updates, Trials, Safety Data
  • Rheumatology Drug Updates, Trials, Safety Data
  • Rheumatology Drug Updates, Trials, Safety Data

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)